世界の患者由来異種移植/PDXモデル市場(~2026年):種類別(マウス、ラット)、腫瘍タイプ別(胃腸、婦人科、血液)、用途別(前臨床医薬品開発、バイオマーカー分析)、エンドユーザー別(製薬、バイオテクノロジー、CRO)

【英語タイトル】Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026

MarketsandMarketsが出版した調査資料(BT5576)・商品コード:BT5576
・発行会社(調査会社):MarketsandMarkets
・発行日:2029年4月23日
・ページ数:171
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
マーケッツアンドマーケッツ社は、世界の患者由来異種移植/PDXモデル市場規模が2021年140百万ドルから2026年299百万ドルまで、年平均16.4%成長すると予測しています。本調査レポートでは、患者由来異種移植/PDXモデルの世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(マウスモデル、ラットモデル)分析、腫瘍タイプ別(消化管腫瘍モデル、婦人科腫瘍モデル、呼吸器腫瘍モデル、泌尿器腫瘍モデル、血液腫瘍モデル)分析、用途別(前臨床医薬品開発、バイオマーカー分析、がん基本研究)分析、エンドユーザー別(製薬&バイオテクノロジー、委託研究機関、学術&研究機関)分析、地域別分析、競争状況、企業情報などを整理しました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の患者由来異種移植/PDXモデル市場規模:種類別(マウスモデル、ラットモデル)
・世界の患者由来異種移植/PDXモデル市場規模:腫瘍タイプ別(消化管腫瘍モデル、婦人科腫瘍モデル、呼吸器腫瘍モデル、泌尿器腫瘍モデル、血液腫瘍モデル)
・世界の患者由来異種移植/PDXモデル市場規模:用途別(前臨床医薬品開発、バイオマーカー分析、がん基本研究)
・世界の患者由来異種移植/PDXモデル市場規模:エンドユーザー別(製薬&バイオテクノロジー、委託研究機関、学術&研究機関)
・世界の患者由来異種移植/PDXモデル市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period.”
Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.

“The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period”
The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period. This segment’s high growth rate can be attributed to the rising number of clinical trials every year.

“Contract research organizations segment accounted for the highest CAGR”
Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. During the forecast period contract research organizations accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.

“Rat models segment accounted for the highest CAGR”
Based on type, the PDX models market is segmented into mice models and rat models. The rat models segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.

“Respiratory tumor models segment accounted for the highest CAGR”
Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The respiratory tumor models segment accounted for the highest growth rate during the forecast period. The key factor driving this segment’s growth is the increasing incidence of lung cancers globally.

“Asia Pacific: The fastest-growing country in the PDX models market”
The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side – 30%
• By Designation (Supply Side): Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:
• JSR Corporation (Japan)
• WuXi AppTec (China)
• Champions Oncology, Inc. (US)
• THE JACKSON LABORATORY (US)
• Charles River Laboratories (US)
• Oncodesign (France)
• Envigo (US)
• Pharmatest Services (Finland)
• Hera BioLabs (US)
• EPO Berlin-Buch GmbH (Germany)
• Xentech (France)
• Urosphere (France)
• Abnova Corporation (Taiwan)
• Genesis Biotechnology Group (US)
• Explora BioLabs (US)
• Biocytogen (US)
• Living Tumor Laboratory (Canada)
• Bioduro (US)
• Aragen Life Sciences w.e.f, (US)
• Shanghai Lide Biotech Co., Ltd. (China)

Research Coverage:
This report provides a detailed picture of the PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, tumor type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall PDX models market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.2.1 INCLUSIONS & EXCLUSIONS 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED IN THE REPORT 21
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22
1.7 SUMMARY OF CHANGES 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
FIGURE 1 RESEARCH DESIGN 24
2.1.1 SECONDARY DATA 25
2.1.2 PRIMARY DATA 25
FIGURE 2 PRIMARY SOURCES 26
FIGURE 3 PDX MODELS MARKET: BREAKDOWN OF PRIMARIES 26
2.1.2.1 Key industry insights 27
2.2 MARKET SIZE ESTIMATION 28
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2020 28
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020 29
FIGURE 6 PDX MODELS MARKET: CAGR PROJECTIONS, 2021–2026 30
FIGURE 7 PDX MODELS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 31
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 32
FIGURE 8 DATA TRIANGULATION METHODOLOGY 32
2.4 RESEARCH ASSUMPTIONS 33
2.5 RISK ANALYSIS 33
3 EXECUTIVE SUMMARY 34
FIGURE 9 PDX MODELS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 34
FIGURE 10 PDX MODELS MARKET, BY TUMOR TYPE, 2021 VS. 2026 (USD MILLION) 35
FIGURE 11 PDX MODELS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 35
FIGURE 12 PDX MODELS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 36
FIGURE 13 PDX MODELS MARKET: GEOGRAPHIC SNAPSHOT 37
4 PREMIUM INSIGHTS 38
4.1 PDX MODELS MARKET OVERVIEW 38
FIGURE 14 INCREASING SUPPORT FOR CANCER RESEARCH FROM PUBLIC AND PRIVATE SECTORS AND GROWING DEMAND FOR PRECISION MEDICINE ARE KEY GROWTH DRIVERS 38
4.2 NORTH AMERICA: PDX MODELS MARKET, MARKET SHARE (2020) 39
FIGURE 15 MICE MODELS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN PDX MODELS MARKET IN 2020 39
4.3 PDX MODELS MARKET SHARE, BY END USER (2020) 39
FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED THE LARGEST SHARE OF THE PDX MODELS MARKET IN 2020 39
4.4 PDX MODELS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 40
FIGURE 17 CHINA TO WITNESS THE HIGHEST GROWTH IN THE PDX MODELS MARKET DURING THE FORECAST PERIOD 40
5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
FIGURE 18 PDX MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
TABLE 1 PDX MODELS MARKET: IMPACT ANALYSIS 42
5.2.1 DRIVERS 42
5.2.1.1 Growing demand for personalized medicine 42
5.2.1.2 Continuous support for cancer research from the public & private sectors 43
5.2.1.3 Rising pharma R&D 44
5.2.2 RESTRAINTS 44
5.2.2.1 High cost of personalized PDX models 44
5.2.2.2 Stringent guidelines for the use of animal models in cancer research 44
5.2.3 OPPORTUNITIES 45
5.2.3.1 Rising demand for humanized PDX models 45
5.2.4 CHALLENGES 46
5.2.4.1 Limitations of PDX models 46
5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE PDX MODELS MARKET 46
5.4 TECHNOLOGICAL ANALYSIS 47
5.5 PRICING ANALYSIS 48
5.6 VALUE CHAIN ANALYSIS 48
FIGURE 19 VALUE CHAIN ANALYSIS OF PDX MODELS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE 48
FIGURE 20 VALUE CHAIN: CREATION OF PDX MODELS—MAXIMUM VALUE IS ADDED DURING THE IMPLANTATIONS OF TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS 49
5.7 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET 50
FIGURE 21 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET 50
TABLE 2 SUPPLY CHAIN ECOSYSTEM 51
5.8 PORTER’S FIVE FORCES ANALYSIS 52
TABLE 3 PDX MODELS MARKET: PORTER’S FIVE FORCES ANALYSIS 52
5.8.1 THREAT OF NEW ENTRANTS 52
5.8.2 THREAT OF SUBSTITUTES 52
5.8.3 BARGAINING POWER OF BUYERS 52
5.8.4 BARGAINING POWER OF SUPPLIERS 52
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 52
5.9 REGULATORY ANALYSIS 53
5.9.1 NORTH AMERICA 53
5.9.2 EUROPE 54
5.9.3 ASIA PACIFIC 55
5.9.3.1 China 55
5.9.3.2 Japan 55
5.9.3.3 India 56
5.9.3.4 Australia 57
5.9.4 LATIN AMERICA 57
5.9.5 MIDDLE EAST & AFRICA 57
5.10 PATENT ANALYSIS 58
FIGURE 22 PATENTS GRANTED FOR PDX MODELS, JANUARY 2010–DECEMBER 2020 58
6 PDX MODELS MARKET, BY TYPE 59
6.1 INTRODUCTION 60
TABLE 4 PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 60
6.2 MICE MODELS 60
6.2.1 EASE OF PROCUREMENT AND WIDE AVAILABILITY OF MICE MODELS DRIVE THE GROWTH OF THIS SEGMENT 60
TABLE 5 PDX MICE MODELS MARKET, BY REGION, 2019–2026 (USD MILLION) 61
TABLE 6 NORTH AMERICA: PDX MICE MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 61
TABLE 7 EUROPE: PDX MICE MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 61
TABLE 8 ASIA PACIFIC: PDX MICE MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 62
6.3 RAT MODELS 62
6.3.1 FACTORS SUCH AS EASIER SURGICAL MANIPULATION AND LARGER TUMOR SIZE WILL SUPPORT USE OF RAT MODELS 62
TABLE 9 PDX RAT MODELS MARKET, BY REGION, 2019–2026 (USD MILLION) 62
TABLE 10 NORTH AMERICA: PDX RAT MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 63
TABLE 11 EUROPE: PDX RAT MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 63
TABLE 12 ASIA PACIFIC: PDX RAT MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 63

7 PDX MODELS MARKET, BY TUMOR TYPE 64
7.1 INTRODUCTION 65
TABLE 13 PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 65
7.2 GASTROINTESTINAL TUMOR MODELS 65
7.2.1 NEWLY DEVELOPED GASTROINTESTINAL TUMOR MODELS MIMIC THE TUMOR BETTER THAN PREVIOUS MODELS 65
TABLE 14 GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION,
2019–2026 (USD MILLION) 66
TABLE 15 NORTH AMERICA: GASTROINTESTINAL TUMOR MODELS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 66
TABLE 16 EUROPE: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 66
TABLE 17 ASIA PACIFIC: GASTROINTESTINAL TUMOR MODELS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 67
7.3 GYNECOLOGICAL TUMOR MODELS 67
7.3.1 HIGH INCIDENCE OF TARGET CANCERS HAS DRIVEN DEMAND FOR TUMOR MODELS 67
TABLE 18 GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION,
2019–2026 (USD MILLION) 67
TABLE 19 NORTH AMERICA: GYNECOLOGICAL TUMOR MODELS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 68
TABLE 20 EUROPE: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 68
TABLE 21 ASIA PACIFIC: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 68
7.4 RESPIRATORY TUMOR MODELS 69
7.4.1 RISING PREVALENCE OF LUNG CANCER TO DRIVE MARKET GROWTH 69
TABLE 22 RESPIRATORY TUMOR MODELS MARKET, BY REGION,
2019–2026 (USD MILLION) 69
TABLE 23 NORTH AMERICA: RESPIRATORY TUMOR MODELS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 69
TABLE 24 EUROPE: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 70
TABLE 25 ASIA PACIFIC: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 70
7.5 UROLOGICAL TUMOR MODELS 70
7.5.1 COMPANIES ARE FOCUSING ON EXPANDING THEIR PORTFOLIO FOR UROLOGICAL CANCERS 70
TABLE 26 UROLOGICAL TUMOR MODELS MARKET, BY REGION,
2019–2026 (USD MILLION) 71
TABLE 27 NORTH AMERICA: UROLOGICAL TUMOR MODELS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 71
TABLE 28 EUROPE: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 71
TABLE 29 ASIA PACIFIC: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 72

7.6 HEMATOLOGICAL TUMOR MODELS 72
7.6.1 NEW STRAINS SUCH AS NSG AND NOG HAVE INCREASED THE LIFE SPAN OF HEMATOLOGICAL TUMOR MODELS 72
TABLE 30 HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION,
2019–2026 (USD MILLION) 72
TABLE 31 NORTH AMERICA: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 73
TABLE 32 EUROPE: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 73
TABLE 33 ASIA PACIFIC: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 73
7.7 OTHER TUMOR MODELS 74
TABLE 34 OTHER TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 35 NORTH AMERICA: OTHER TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 74
TABLE 36 EUROPE: OTHER TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 75
TABLE 37 ASIA PACIFIC: OTHER TUMOR MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 75
8 PDX MODELS MARKET, BY APPLICATION 76
8.1 INTRODUCTION 77
TABLE 38 PDX MODELS MARKET, BY APPLICATION, 2021–2026 (USD MILLION) 77
8.2 PRECLINICAL DRUG DEVELOPMENT 77
8.2.1 RISE IN NUMBER OF CLINICAL TRIALS WILL DRIVE THE GROWTH OF THIS SEGMENT 77
TABLE 39 PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION) 78
TABLE 40 NORTH AMERICA: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 41 EUROPE: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 42 ASIA PACIFIC: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION) 79
8.3 BIOMARKER ANALYSIS 79
8.3.1 GROWING INTEREST IN PRECISION MEDICINE WILL CONTRIBUTE TO THE DEMAND FOR PDX MODELS FOR BIOMARKER ANALYSIS 79
TABLE 43 PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION,
2019–2026 (USD MILLION) 80
TABLE 44 NORTH AMERICA: PDX MODELS MARKET FOR BIOMARKER ANALYSIS,
BY COUNTRY, 2019–2026 (USD MILLION) 80
TABLE 45 EUROPE: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION) 80
TABLE 46 ASIA PACIFIC: PDX MODELS MARKET FOR BIOMARKER ANALYSIS,
BY COUNTRY, 2019–2026 (USD MILLION) 81
8.4 BASIC CANCER RESEARCH 81
8.4.1 RISING FUNDING FOR CANCER RESEARCH WILL DRIVE MARKET GROWTH
IN THIS SEGMENT 81
TABLE 47 PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY REGION,
2019–2026 (USD MILLION) 82
TABLE 48 NORTH AMERICA: PDX MODELS MARKET FOR BASIC CANCER RESEARCH,
BY COUNTRY, 2019–2026 (USD MILLION) 82
TABLE 49 EUROPE: PDX MODELS MARKET FOR BASIC CANCER RESEARCH,
BY COUNTRY, 2019–2026 (USD MILLION) 82
TABLE 50 ASIA PACIFIC: PDX MODELS MARKET FOR BASIC CANCER RESEARCH,
BY COUNTRY, 2019–2026 (USD MILLION) 83
9 PDX MODELS MARKET, BY END USER 84
9.1 INTRODUCTION 85
TABLE 51 PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 85
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 85
9.2.1 RISING COLLABORATION BETWEEN PHARMA & BIOTECH COMPANIES FOR DEVELOPING CANCER THERAPEUTICS 85
TABLE 52 PDX MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION) 86
TABLE 53 NORTH AMERICA: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 86
TABLE 54 EUROPE: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 87
TABLE 55 ASIA PACIFIC: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 87
9.3 CONTRACT RESEARCH ORGANIZATIONS 87
9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES WILL DRIVE MARKET GROWTH 87
TABLE 56 PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2019–2026 (USD MILLION) 88
TABLE 57 NORTH AMERICA: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 58 EUROPE: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 59 ASIA PACIFIC: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 89
9.4 ACADEMIC & RESEARCH INSTITUTIONS 89
9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE WILL CONTRIBUTE TO THE GROWTH OF THIS SEGMENT 89
TABLE 60 PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS,
BY REGION, 2019–2026 (USD MILLION) 90
TABLE 61 NORTH AMERICA: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 62 EUROPE: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 63 ASIA PACIFIC: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION) 91

10 PDX MODELS MARKET, BY REGION 92
10.1 INTRODUCTION 93
TABLE 64 PDX MODELS MARKET, BY REGION, 2019–2026 (USD MILLION) 93
10.2 NORTH AMERICA 94
FIGURE 23 NORTH AMERICA: PDX MODELS MARKET SNAPSHOT 94
TABLE 65 NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 95
TABLE 66 NORTH AMERICA: PDX MODELS MARKET, BY TYPE,
2019–2026 (USD MILLION) 95
TABLE 67 NORTH AMERICA: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 95
TABLE 68 NORTH AMERICA: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 96
TABLE 69 NORTH AMERICA: PDX MODELS MARKET, BY END USER,
2019–2026 (USD MILLION) 96
10.2.1 US 96
10.2.1.1 Growing focus on cancer research in the US will drive market growth 96
TABLE 70 US: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 71 US: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 97
TABLE 72 US: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 98
TABLE 73 US: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 98
10.2.2 CANADA 98
10.2.2.1 Growth in Canada can be attributed to rising funding for stem cell research in the country 98
TABLE 74 CANADA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 99
TABLE 75 CANADA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 99
TABLE 76 CANADA: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 100
TABLE 77 CANADA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 100
10.3 EUROPE 100
TABLE 78 EUROPE: PDX MODELS MARKET, BY COUNTRY/REGION, 2019–2026 (USD MILLION) 101
TABLE 79 EUROPE: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 101
TABLE 80 EUROPE: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 101
TABLE 81 EUROPE: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 102
TABLE 82 EUROPE: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 102
10.3.1 GERMANY 102
10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth 102
TABLE 83 GERMANY: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 103
TABLE 84 GERMANY: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 103
TABLE 85 GERMANY: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 103
TABLE 86 GERMANY: PDX MODELS MARKET, BY END USER,
2019–2026 (USD MILLION) 104
10.3.2 UK 104
10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth 104
TABLE 87 UK: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 104
TABLE 88 UK: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 105
TABLE 89 UK: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 105
TABLE 90 UK: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 105
10.3.3 FRANCE 106
10.3.3.1 Increasing government funding for cancer research 106
TABLE 91 FRANCE: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 106
TABLE 92 FRANCE: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 106
TABLE 93 FRANCE: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 107
TABLE 94 FRANCE: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 107
10.3.4 ROE 107
TABLE 95 ROE: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 96 ROE: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 108
TABLE 97 ROE: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 108
TABLE 98 ROE: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 109
10.4 ASIA PACIFIC 109
FIGURE 24 ASIA PACIFIC: PDX MODELS MARKET SNAPSHOT 110
TABLE 99 ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 110
TABLE 100 ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 111
TABLE 101 ASIA PACIFIC: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 111
TABLE 102 ASIA PACIFIC: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 111
TABLE 103 ASIA PACIFIC: PDX MODELS MARKET, BY END USER,
2019–2026 (USD MILLION) 112
10.4.1 CHINA 112
10.4.1.1 The growing pharmaceutical industry and rising number of CROs in the country will drive market growth 112
TABLE 104 CHINA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 105 CHINA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 113
TABLE 106 CHINA: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 113
TABLE 107 CHINA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 114
10.4.2 JAPAN 114
10.4.2.1 Research collaborations and growing geriatric population—key growth drivers in Japan 114
TABLE 108 JAPAN: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 109 JAPAN: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION) 115
TABLE 110 JAPAN: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 115
TABLE 111 JAPAN: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 116
10.4.3 REST OF ASIA PACIFIC 116
TABLE 112 ROAPAC: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 113 ROAPAC: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 117
TABLE 114 ROAPAC: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 117
TABLE 115 ROAPAC: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION) 118
10.5 LATIN AMERICA 118
10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET 118
TABLE 116 LATIN AMERICA: PDX MODELS MARKET, BY TYPE,
2019–2026 (USD MILLION) 118
TABLE 117 LATIN AMERICA: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 119
TABLE 118 LATIN AMERICA: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 119
TABLE 119 LATIN AMERICA: PDX MODELS MARKET, BY END USER,
2019–2026 (USD MILLION) 119
10.6 MIDDLE EAST & AFRICA 120
10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D 120
TABLE 120 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 121 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TUMOR TYPE,
2019–2026 (USD MILLION) 121
TABLE 122 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 121
TABLE 123 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY END USER,
2019–2026 (USD MILLION) 121
11 COMPETITIVE LANDSCAPE 122
11.1 OVERVIEW 122
11.2 MARKET EVALUATION FRAMEWORK 122
TABLE 124 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS—THE MAJOR STRATEGIES ADOPTED BY PLAYERS 122
11.3 MARKET SHARE ANALYSIS 123
FIGURE 25 PDX MODELS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 123
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 124
FIGURE 26 TOP MARKET PLAYERS DOMINATE THE PDX MODELS MARKET 124
11.5 COMPANY EVALUATION QUADRANT 124
11.5.1 STARS 125
11.5.2 EMERGING LEADERS 125
11.5.3 PERVASIVE 125
11.5.4 EMERGING COMPANIES 125
FIGURE 27 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT, 2020 126
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 127
11.6.1 PROGRESSIVE COMPANIES 127
11.6.2 STARTING BLOCKS 127
11.6.3 RESPONSIVE COMPANIES 127
11.6.4 DYNAMIC COMPANIES 127
FIGURE 28 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 128
11.7 COMPANY PRODUCT FOOTPRINT 129
TABLE 125 PRODUCT PORTFOLIO ANALYSIS: PDX MODELS MARKET (2020) 129
11.8 COMPANY GEOGRAPHIC FOOTPRINT 130
TABLE 126 GEOGRAPHIC REVENUE MIX: PDX MODELS MARKET (2020) 130
11.9 COMPETITIVE SCENARIO 131
11.9.1 PDX MODELS MARKET: PRODUCT & SERVICE LAUNCHES,
JANUARY 2018–FEBRUARY 2021 131
11.9.2 PDX MODELS MARKET: DEALS, JANUARY 2019–FEBRUARY 2021 131
11.9.3 PDX MODELS MARKET: OTHER DEVELOPMENTS,
JANUARY 2018–FEBRUARY 2021 132
12 COMPANY PROFILES 133
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 KEY MARKET PLAYERS 133
12.1.1 JSR CORPORATION 133
FIGURE 29 JSR CORPORATION: COMPANY SNAPSHOT (2019) 134
12.1.2 WUXI APPTEC 137
FIGURE 30 WUXI APPTEC: COMPANY SNAPSHOT (2020) 137
12.1.3 THE JACKSON LABORATORY 140
FIGURE 31 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019) 140
12.1.4 CHARLES RIVER LABORATORIES 143
FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020) 144
12.1.5 CHAMPIONS ONCOLOGY 147
FIGURE 33 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2020) 147
12.1.6 ONCODESIGN 150
FIGURE 34 ONCODESIGN: COMPANY SNAPSHOT (2020) 150
12.1.7 ENVIGO 151
12.1.8 PHARMATEST SERVICES 153
12.1.9 HERA BIOLABS 154
12.1.10 EPO BERLIN-BUCH GMBH 155
12.1.11 XENTECH 156
12.1.12 UROSPHERE 158
12.2 OTHER PLAYERS 159
12.2.1 ABNOVA CORPORATION 159
12.2.2 GENESIS BIOTECHNOLOGY GROUP 160
12.2.3 EXPLORA BIOLABS 161
12.2.4 BIOCYTOGEN 163
12.2.5 LIVING TUMOR LABORATORY 163
12.2.6 BIODURO 164
12.2.7 ARAGEN LIFE SCIENCES W.E.F 164
12.2.8 SHANGHAI LIDE BIOTECH 165
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 166
13.1 DISCUSSION GUIDE 166
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 170
13.3 AVAILABLE CUSTOMIZATIONS 172
13.4 RELATED REPORTS 172
13.5 AUTHOR DETAILS 173



★調査レポート[世界の患者由来異種移植/PDXモデル市場(~2026年):種類別(マウス、ラット)、腫瘍タイプ別(胃腸、婦人科、血液)、用途別(前臨床医薬品開発、バイオマーカー分析)、エンドユーザー別(製薬、バイオテクノロジー、CRO)] (コード:BT5576)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の患者由来異種移植/PDXモデル市場(~2026年):種類別(マウス、ラット)、腫瘍タイプ別(胃腸、婦人科、血液)、用途別(前臨床医薬品開発、バイオマーカー分析)、エンドユーザー別(製薬、バイオテクノロジー、CRO)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆